Influenza regulation of epithelial pneumococcal host defense.
Influenza regulation of epithelial pneumococcal host defense.
批准号:
10682497
负责人:
Kevin S Harrod
金额:
$37.13万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-10 至 2024-08-31
关键词:
AcuteAddressAntiviral TherapyAttenuatedBacterial InfectionsBacterial PneumoniaBicarbonatesChemosensitizationClinicalCystic Fibrosis Transmembrane Conductance RegulatorDataDiseaseEpitheliumExperimental ModelsFDA approvedFluMistFunctional disorderGoalsGrantHealthHeart DiseasesHospitalizationHost DefenseHumanImmunologicsIn VitroInfectionInfluenzaInfluenza A virusInternationalInterventionInvestigationIon ChannelIonsIronKidney DiseasesKnowledgeLaboratoriesLeadLinkLiquid substanceLungLung infectionsMediatingMediatorMethodologyModelingMolecularMusPathogenesisPharmaceutical PreparationsPlayPneumococcal InfectionsPneumoniaPositioning AttributePredispositionPreventionProphylactic treatmentProteinsPublishingRegulationRespiratory SystemRoleSecondary toSepsisStreptococcus pneumoniaeSurfaceTestingTissuesVaccinesVirus Diseasesairway epitheliumairway surface liquidbactericideco-infectioncofactorendoplasmic reticulum stressexperimental studyglobal healthhealth disparityhealthy volunteerhuman diseasehuman modelin vivoin vivo Modelinfluenza infectionmouse modelnovelpathogenic bacteriapharmacologicsecondary infectiontranslational study
中文摘要
项目总结
流感感染仍然是一个国际卫生问题,尽管有全球监测、有效的疫苗和
抗病毒治疗。继发性细菌感染正在成为人类疾病的重要原因
然而,关于流感如何增加细菌感染的易感性,人们知之甚少。
肺炎球菌感染是流感后继发细菌感染的最常见原因,以及
肺外肺炎球菌感染正在成为急性心脏和肾脏疾病的主要原因
在人类身上。我们对继发性肺炎球菌感染的认识存在重大差距,没有更大的差距
肺上皮在流感后细菌宿主防御中的作用。此应用程序将
从机械上解构流感如何增加肺部肺炎球菌感染的易感性
并将填补我们目前关于流感继发性细菌知识的重要空白。
感染。本实验室在实验性肺部感染和原代分化肺上皮细胞方面的专业知识
文化模型使我们在这次调查中处于独特的地位。在这里,我们提出了三种机械驱动
已发表的初步数据清楚地支持我们的科学假设,即流感-
上皮离子失调的驱动变化导致气道表面液体酸化
对肺炎球菌感染的易感性。具体地说,目标1将阐明肺上皮的关键作用
流感后对肺炎球菌的易感性。目标2将从机械上决定上皮离子
功能障碍导致呼吸道上皮细胞表面液体酸化是其潜在的分子机制。
最后,目标3将阐明流感后肺炎球菌感染增加对肺炎的影响。
和播散性肺外疾病,同时探索FDA批准的改变用途的药物的干预措施。
总而言之,这项提议将提出一种全新的流感媒介潜在机制
对肺炎球菌感染的易感性,将建立一个人体实验模型来研究流感-
肺炎球菌混合感染,并评估可迅速实施的药物干预措施
预防流感继发性肺炎球菌感染。
英文摘要
PROJECT SUMMARY
Influenza infection remains an international health concern despite global surveillance, effective vaccines, and
antiviral therapy. Secondary bacterial infections are emerging as an important cause of human disease to
influenza, however little is known regarding how influenza increases susceptibility to bacterial infection.
Pneumococcal infection is the most common cause of secondary bacterial infection postinfluenza, and
extrapulmonary pneumococcal infections are emerging as leading causes of acute cardiac and renal disease
in humans. Significant gaps in our knowledge around secondary pneumococcal infection exists, none larger
than the role of the lung epithelium in bacterial host defense following influenza. This application will
mechanistically deconstruct how influenza enhances susceptibility to pneumococcal infection in the lung
epithelium, and will fill important gaps in our current knowledge regarding influenza secondary bacterial
infection. Our laboratory's expertise in experimental lung infection and primary differentiated lung epithelial
culture models puts us uniquely positioned for this investigation. Here we put forth three mechanistically driven
aims supported by published and preliminary data clearly supporting our scientific premise that influenza-
driven changes in epithelial ion dysregulation confer airway surface fluid acidification that enhances
susceptibility to pneumococcal infection. Specifically, Aim 1 will elucidate the critical role of the lung epithelium
in susceptibility to pneumococci after influenza. Aim 2 will mechanistically determine epithelium ion
dysfunction leading to acidification the airway epithelial surface fluid as the underlying molecular mechanism.
Lastly, Aim 3 will elucidate the impact of increased pneumococcal infection postinfluenza in vivo in pneumonia
and disseminated extrapulmonary disease, while exploring interventions of repurposed FDA approved drugs.
Collectively, this proposal will put forth an entirely novel underlying mechanism for influenza-mediated
susceptibility to pneumococcal infection, will establish a human experimental model to study influenza-
pneumococcal coinfections, and evaluate pharmacologic interventions that could be implemented rapidly for
prophylaxis to secondary pneumococcal infections to influenza.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Influenza regulation of epithelial pneumococcal host defense.
-
批准号:10260454
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Kevin S Harrod
-
依托单位:
Influenza regulation of epithelial pneumococcal host defense.
-
批准号:10480875
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Kevin S Harrod
-
依托单位:
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections
-
批准号:8694234
-
项目类别:
-
资助金额:$85.27万
-
财政年份:2014
-
负责人:Kevin S Harrod
-
依托单位:
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections
-
批准号:9056295
-
项目类别:
-
资助金额:$71.77万
-
财政年份:2014
-
负责人:Kevin S Harrod
-
依托单位:
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections
-
批准号:9112774
-
项目类别:
-
资助金额:$96.44万
-
财政年份:2014
-
负责人:Kevin S Harrod
-
依托单位:
Lung Transcriptional Regulation During Disease
-
批准号:6710666
-
项目类别:
-
资助金额:$7.73万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
Lung Transcriptional Regulation During Disease
-
批准号:6556988
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP Promoter Function and Tumor Necrosis Factor
-
批准号:6679064
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP Promoter Function and Tumor Necrosis Factor
-
批准号:7078076
-
项目类别:
-
资助金额:$9.9万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP Promoter Function and Tumor Necrosis Factor
-
批准号:6927143
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
Lung Transcriptional Regulation During Disease
-
批准号:7022236
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP Promoter Function and Tumor Necrosis Factor
-
批准号:6785311
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
Lung Transcriptional Regulation During Disease
-
批准号:7191570
-
项目类别:
-
资助金额:$8.45万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP Promoter Function and Tumor Necrosis Factor
-
批准号:7098808
-
项目类别:
-
资助金额:$48.73万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
Lung Transcriptional Regulation During Disease
-
批准号:6859395
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2003
-
负责人:Kevin S Harrod
-
依托单位:
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION
-
批准号:6390988
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Kevin S Harrod
-
依托单位:
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION
-
批准号:6199454
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Kevin S Harrod
-
依托单位:
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION
-
批准号:6527966
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Kevin S Harrod
-
依托单位:
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION
-
批准号:6610960
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Kevin S Harrod
-
依托单位:
海外基金